82 related articles for article (PubMed ID: 14764750)
21. Diagnostic value of the acid-labile subunit in acromegaly: evaluation in comparison with insulin-like growth factor (IGF) I, and IGF-binding protein-1, -2, and -3.
Arosio M; Garrone S; Bruzzi P; Faglia G; Minuto F; Barreca A
J Clin Endocrinol Metab; 2001 Mar; 86(3):1091-8. PubMed ID: 11238491
[TBL] [Abstract][Full Text] [Related]
22. Postoperative evaluation of patients with acromegaly: clinical significance and timing of oral glucose tolerance testing and measurement of (free) insulin-like growth factor I, acid-labile subunit, and growth hormone-binding protein levels.
Feelders RA; Bidlingmaier M; Strasburger CJ; Janssen JA; Uitterlinden P; Hofland LJ; Lamberts SW; van der Lely AJ; de Herder WW
J Clin Endocrinol Metab; 2005 Dec; 90(12):6480-9. PubMed ID: 16159936
[TBL] [Abstract][Full Text] [Related]
23. Octreotide LAR vs. surgery in newly diagnosed patients with acromegaly: a randomized, open-label, multicentre study.
Colao A; Cappabianca P; Caron P; De Menis E; Farrall AJ; Gadelha MR; Hmissi A; Rees A; Reincke M; Safari M; T'Sjoen G; Bouterfa H; Cuneo RC
Clin Endocrinol (Oxf); 2009 May; 70(5):757-68. PubMed ID: 19178516
[TBL] [Abstract][Full Text] [Related]
24. Octreotide as primary therapy for acromegaly.
Newman CB; Melmed S; George A; Torigian D; Duhaney M; Snyder P; Young W; Klibanski A; Molitch ME; Gagel R; Sheeler L; Cook D; Malarkey W; Jackson I; Vance ML; Barkan A; Frohman L; Kleinberg DL
J Clin Endocrinol Metab; 1998 Sep; 83(9):3034-40. PubMed ID: 9745397
[TBL] [Abstract][Full Text] [Related]
25. Should we still use glucose-suppressed growth hormone levels for the evaluation of acromegaly?
Colao A; Lombardi G
J Clin Endocrinol Metab; 2008 Apr; 93(4):1181-2. PubMed ID: 18390816
[No Abstract] [Full Text] [Related]
26. Discordant nadir GH after oral glucose and IGF-I levels on treated acromegaly: refining the biochemical markers of mild disease activity.
Elias PC; Lugao HB; Pereira MC; Machado HR; Castro Md; Moreira AC
Horm Metab Res; 2010 Jan; 42(1):50-5. PubMed ID: 19798623
[TBL] [Abstract][Full Text] [Related]
27. Medical therapy in patients with acromegaly: predictors of response and comparison of efficacy of dopamine agonists and somatostatin analogues.
Sherlock M; Fernandez-Rodriguez E; Alonso AA; Reulen RC; Ayuk J; Clayton RN; Holder G; Sheppard MC; Bates A; Stewart PM
J Clin Endocrinol Metab; 2009 Apr; 94(4):1255-63. PubMed ID: 19158203
[TBL] [Abstract][Full Text] [Related]
28. Recent developments in the therapy of acromegaly.
Paisley AN; Trainer PJ
Expert Opin Investig Drugs; 2006 Mar; 15(3):251-6. PubMed ID: 16503762
[TBL] [Abstract][Full Text] [Related]
29. Pitfalls in the diagnosis of acromegaly.
Pokrajac-Simeunovic A; Trainer PJ
Horm Res; 2004; 62 Suppl 3():74-8. PubMed ID: 15539804
[TBL] [Abstract][Full Text] [Related]
30. [Consensus on the change of criteria for cure of acromegaly during the last decade].
Kovács GL; Dénes J; Hubina E; Kovács L; Czirják S; Góth M
Orv Hetil; 2011 May; 152(18):703-8. PubMed ID: 21498158
[TBL] [Abstract][Full Text] [Related]
31. Pioglitazone in acromegaly - an open-label, prospective study.
Kim DD; Goh J; Panossian Z; Gamble G; Holdaway I; Grey A
Clin Endocrinol (Oxf); 2012 Oct; 77(4):575-8. PubMed ID: 22512403
[TBL] [Abstract][Full Text] [Related]
32. Serum leptin levels in patients with acromegaly before and after correction of hypersomatotropism by trans-sphenoidal surgery.
Damjanović SS; Petakov MS; Raicević S; Micić D; Marinković J; Dieguez C; Casanueva FF; Popović V
J Clin Endocrinol Metab; 2000 Jan; 85(1):147-54. PubMed ID: 10634378
[TBL] [Abstract][Full Text] [Related]
33. What is the diagnosis? Acromegaly.
Muthusamy K; Bingham RJ
Endocr Pract; 2010; 16(3):531. PubMed ID: 20061286
[No Abstract] [Full Text] [Related]
34. Pituitary magnetic resonance imaging is not required in the postoperative follow-up of acromegalic patients with long-term biochemical cure after transsphenoidal surgery.
Zirkzee EJ; Corssmit EP; Biermasz NR; Brouwer PA; Wiggers-De Bruine FT; Kroft LJ; Van Buchem MA; Roelfsema F; Pereira AM; Smit JW; Romijn JA
J Clin Endocrinol Metab; 2004 Sep; 89(9):4320-4. PubMed ID: 15356027
[TBL] [Abstract][Full Text] [Related]
35. Evidence for the use of igf-I as a predictor of mortality in acromegaly is lacking.
Ayuk J; Sheppard MC; Clayton RN; Bates AS; Stewart PM
J Clin Endocrinol Metab; 2004 Nov; 89(11):5867-8; author reply 5868. PubMed ID: 15531556
[No Abstract] [Full Text] [Related]
36. The utility of oral glucose tolerance testing for diagnosis and assessment of treatment outcomes in 166 patients with acromegaly.
Carmichael JD; Bonert VS; Mirocha JM; Melmed S
J Clin Endocrinol Metab; 2009 Feb; 94(2):523-7. PubMed ID: 19033371
[TBL] [Abstract][Full Text] [Related]
37. Long-term follow-up results of postoperative radiotherapy in 36 patients with acromegaly.
Biermasz NR; van Dulken H; Roelfsema F
J Clin Endocrinol Metab; 2000 Jul; 85(7):2476-82. PubMed ID: 10902796
[TBL] [Abstract][Full Text] [Related]
38. Value of growth hormone dynamics and somatomedin C (insulin-like growth factor I) levels in predicting the long-term benefit after transsphenoidal surgery for acromegaly.
Arafah BM; Rosenzweig JL; Fenstermaker R; Salazar R; McBride CE; Selman W
J Lab Clin Med; 1987 Mar; 109(3):346-54. PubMed ID: 3102658
[TBL] [Abstract][Full Text] [Related]
39. The role of radiotherapy in acromegaly.
van der Lely AJ; de Herder WW; Lamberts SW
J Clin Endocrinol Metab; 1997 Oct; 82(10):3185-6. PubMed ID: 9329335
[No Abstract] [Full Text] [Related]
40. Monitoring the response to treatment in acromegaly.
Clemmons DR; Strasburger C
J Clin Endocrinol Metab; 2004 Nov; 89(11):5289-91. PubMed ID: 15531471
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
